•
Nivolumab is the first agent to demonstrate a significant improvement in survival
in patients with SCCHN who progress after platinum-based therapy in a global,
phase 3 comparative trial
– Nivolumab doubled the 1-year survival rate: 36% with nivolumab compared to 17% for
investigator’s choice therapy
•
Nivolumab demonstrated a survival benefit in the overall study population regardless
of PD-L1 expression or p16 status
•
Magnitude of OS benefit of nivolumab vs investigator’s choice was greater in patients
expressing PD-L1, and increasing PD-L1 expression did not result in further benefit
•
There were fewer treatment-related adverse events with nivolumab vs investigator’s
choice therapy
Conclusions
Nivolumab in R/M SCCHN After Platinum Therapy
